Snoring can indicate potential health risks as well as cause sleepless nights for your significant other. Many products on the market claim to have the perfect product to stop snoring. Consumers who have purchased these products can attest that many of them do not work. The Stop Snoring Program may be the answer to your snoring problem.

The Stop Snoring Program is simply a set of instructions and minor lifestyle changes that one must follow in order to obtain the desired results. Many doctors have been astounded by the results of their patients who have followed the program. Developers of this program have experienced the discomfort of sleepless and restless nights due to snoring. They have designed this program specifically tailored to allow snorers to sleep restfully, without snoring. In many cases only minor lifestyle changes must be made in order to experience a snore-free night.

Those who suffer from sleep apnea need not be concerned with the affect the stop snoring program will have on them. In most cases those who follow the program, will have fewer issues with sleep apnea. Many who have used the Stop Snoring Program have reduced sleep apnea symptoms. Many others have no sleep apnea symptoms at all after following the program.

By following the Stop Snoring Program, you will no longer have to experience the discomfort of being awakened due to your own snoring. You will no longer disturb others sleep. Many people who have used the program have indicated that have returned to their bed after years of sleeping apart due to snoring.

Snoring can be indicative of many health problems. We are aware of issues such as sleep apnes. Snoring can also lead to hypertension due to unrestful sleep. Snoring can be a sign of other breathing problems as well. It is important to take steps to get a restful sleep without snoring. The Stop Snoring Program is designed to help you achieve that goal.

There will be no need to purchase those unsightly strips that fit across your nose. You will no longer be the outcast in the bedroom. The health risks that are associated with snoring will be diminished. There is no better time to begin the End Snoring Program than right now! This program will allow you to get a restful sleep, allow your partner a restful sleep, and allow you to wake feeling ready for your day.

Ever slept close to a snorer and it left you feeling like you just wanted to shake them hard out of their sleep to stop the snoring? Snoring can be quite irritating and disturbing. It is that involuntary and sometimes unbearable sound produced during sleep and is mostly triggered by the vibration of the soft palate as it hits against the uvula. Excess tissues around the upper throat area are what mostly contribute to these sounds.

One of the remedies that i am going to talk about is the snoring surgery which is an effective cure to snoring and which works very fast. Due to the growing technological knowledge that cuts across the globe, there are many new techniques and machinery that have come up to deal with this simple procedure. There are many types of surgeries for snoring as we shall soon find out.

One of them is the uvulo palatopharyngoplasty which is also popularly known as palatopharyngoplasty. It aims at enlarging the throat at the tonsular level. The tonsils, part of the soft palate and the uvula are removed to create space for the airway hence vibration is done away with. Another snoring surgery is the one that seeks to shorten the palate through vaporization by the use of the laser. One set back of this surgery is that it is only 555 effective.

Last but not least we have the Cautery-assisted uvulo palatoplasty (CAUP) snoring surgery. It uses the method of burning or heating electrode or a wire to get rid of the uvula. It is effective, less painful and quite easy in comparison with the other surgical methods. Stiffening the tissue in the throat and soft palate is also one of the ways to go. It uses the electrocautery equipment, is very cost effective procedure and the success rate for this surgery is round about 77%.

A paper that appears in the June 2009 issue of Anesthesiology details how AMPAKINE CX717, a Phase II compound created by Irvine, California-based neuroscience company Cortex Pharmaceuticals, demonstrated the rescue of fentanyl-induced respiratory depression and sleep apnea in rats. In this same study, CX717 demonstrated equal efficacy with the opioid antagonist Naloxone, a drug used to counter the effects of opioids on suppression of breathing. CX717 did not, however, interfere with the action of pain-killing opiates. This offers a distinct advantage compared with Naloxone and could provide a novel therapeutic means of treating those patients who are particularly prone to breathing depression with opiates while achieving maximum pain relief.

“The paper focuses on how CX717 enhances the safety of opiate analgesic use during surgery,” explains University of Alberta professor Dr. John J. Greer, who led the animal study. “Patients are usually given an opiate to mediate pain during surgery. Typically, opiates cause respiratory depression in about ten to fifteen percent of patients, which is usually countered by decreasing the amount of opiate. The problem then becomes patients awakening from surgery into pain. The study’s hypothesis was that the AMPAKINE molecule can stimulate breathing without interfering with the ameliorative effects of analgesics.”

AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA-type glutamate receptor. Dr. Greer’s research team demonstrated that certain AMPAKINE compounds stimulate primitive areas of the brain called the pre-Botzinger Complex that controls breathing, without causing side effects. In animal models, the compounds were shown to enhance the respiratory drive and breathing rhythm in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

“We tested this hypothesis with adult Sprague-Dawley rats, which were given the potent opioid fentanyl,” Dr. Greer explains. “When these rats were administered AMPAKINE CX717 after taking the opiate, their breathing came back very strong. During the study, CX717 was shown not only to protect breathing rates; it also demonstrated the potential to prevent upper airways from collapsing. We then co-administered the AMPAKINE with the opiate as a cocktail, and found that the rats did not experience respiratory depression.”

These results suggest that high-risk post-operative surgical patients, including people sixty-five years and older, those suffering from a history of sleep apnea, patients struggling with obesity, those with a history of respiratory disease such as Chronic Obstructive Pulmonary Disease (COPD), and patients on a regimen of heavy background opiates for the treatment of chronic pain, might be given AMPAKINE preemptively in order to reduce the risk of respiratory depression during surgery.

“CX717 appears to allow clinicians to reduce the incidents of respiratory depression during surgery in some cases, and, in other cases, be used as a rescue for people overdosing on opiates,” says Dr. Greer. “CX717 also generalized across families of drugs not limited to opioids. Combinations of alcohol and barbiturates can cause severe instances of respiratory depression, and CX717 was shown to work in these cases as well. This may lead the way in turning these compounds into rescue therapies.”

These animal studies were later replicated in two Phase II respiratory depression clinical studies involving forty human volunteers in Germany. The next step will be the development of CX717 in intravenous form, with repeated Phase II tests in human trials via intravenous dosing.

“These advances will help patients whose pain cannot be treated effectively with opioids due to the unwanted side effect of a depression of breathing,” says Dr. Greer. “Administration of AMPAKINE compounds can overcome this problem and lead to a significant improvement in pain management, as well as guard against deaths caused by opioid overdose.”

For more information, log on to http://www.cortexpharm.com.

Source
Cortex Pharmaceuticals